STAT Plus: China’s biggest-ever Nasdaq biotech IPO comes at an awkward time
Legend Biotech raised more than $400 million in a Nasdaq IPO on Friday, marking the largest U.S. debut for Chinese drug maker. But Legend’s Wall Street success arrives at an uncertain time for Chinese companies, as a bipartisan group of lawmakers is pushing a bill that could force it and scores of other companies off of U.S. exchanges.
Legend, which is headquartered in Nanjing, priced 18.4 million shares at $23 each. Legend’s most advanced treatment, a CAR-T cancer therapy partnered with Johnson & Johnson, demonstrated impressive results in multiple myeloma in data presented last week.
Continue to STAT Plus to read the full story…
Read Original Article: STAT Plus: China’s biggest-ever Nasdaq biotech IPO comes at an awkward time »